Strengthening self -management improves treatment compliance and outcome in hepatitis B patients with decompen-sated cirrhosis treated with entecavir
10.3969/j.issn.1001-5256.2014.10.019
- VernacularTitle:加强自我管理对乙型肝炎肝硬化失代偿期患者恩替卡韦治疗依从性及疗效的影响
- Author:
Yuhua CUI
;
Xiaojuan WEI
;
Huimei LIN
- Publication Type:Journal Article
- Keywords:
hepatitis B,chronic;
liver cirrhosis;
self administration;
entecavir
- From:
Journal of Clinical Hepatology
2014;30(10):1050-1052
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effect of strengthening self -management on the treatment compliance and outcome in hepatitis B patients with decompensated cirrhosis treated with entecavir.Methods A total of 120 hepatitis B patients with decompensated cirrhosis, who received antiviral therapy with entecavir in our hospital from January 2010 to January 2012,were randomly divided into control group (n=60)and intervention group (n =60).Both groups received routine nursing care;in addition,regular telephone follow -up was performed for the intervention group to provide guidance for the self -management during the comprehensive prevention and treatment of decompensated cirrhosis.The two groups were compared in terms of withdrawal rate,rehospitalization rate,hepatitis B virus (HBV)DNA negative conver-sion rate,incidence of primary liver cancer,and mortality one year later.Continuous data were analyzed by t test,and categorical data by chi -square test or Fisher′s exact test.Results The withdrawal rate and rehospitalization rate in the intervention group were 0 and 18.3%, respectively,versus 8.3% and 35% in the control group (P <0.05 for both).The HBV DNA negative conversion rate,incidence of prima-ry liver cancer,and mortality in the intervention group were 90%,3.3%,and 5.3%,versus 88.3%,5%,and 6.7% in the control group (P >0.05 for all).Conclusion Strengthening self -management,as well as regular health education,can improve treatment compliance and promote recovery in hepatitis B patients with decompensated cirrhosis treated with entecavir.
